ZTS earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Hold, P/E 12.28. Updated 2026-07-23.
Zoetis (ZTS) Research Hub
Zoetis (ZTS) trades on NYSE, US in the Healthcare (Drug Manufacturers - General) sector. As of 2026-09-11, shares last closed at 73 USD (-0.42%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 12.28, market cap 31.16B. This hub links to the full technical, earnings and options research available for ZTS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - General) |
|---|---|
| Exchange | NYSE, US |
| Last close | 73 USD (-0.42%) |
| 52-week range | 71 USD – 82.05 USD |
| Trend regime | Range |
| 14-day RSI | 51.1 (Neutral) |
| Trailing P/E | 12.28 |
| Market cap | 31.16B |
| Dividend yield | 2.82% |
| Next earnings | 2026-08-06 |
Available research for ZTS
Covered Call on ZTS: how it works, illustrative setup around the real 73 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ZTS: how it works, illustrative setup around the real 73 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ZTS: how it works, illustrative setup around the real 73 USD price, max profit/loss, breakeven and when to use it. Educational.
ZTS technical analysis: range, last 73 USD, RSI 51.1, 52w range 71 USD–82.05 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ZTS in?
Zoetis (ZTS) is classified under Healthcare (Drug Manufacturers - General), listed on NYSE, US.
Is ZTS in an uptrend or downtrend?
As of 2026-09-11, ZTS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ZTS's trailing P/E ratio?
ZTS's trailing P/E is 12.28, with a market cap of 31.16B. See the earnings research page for full valuation detail.
When does ZTS next report earnings?
ZTS is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of 1.85 USD.